CCDC85C Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population prepared from the human Raji B lymphocyte cell line, designed to disrupt the CCDC85C gene. This product provides a heterogeneous mixture of cells carrying various gene-disrupting edits, ensuring a functional knockout at the population level. Such polyclonal models avoid the potential artifacts of clonal selection and enable statistically robust studies of gene function in a context that better represents the diversity of genetic perturbations.
The Raji cell line, derived from a Burkitt’s lymphoma patient, is a well-established lymphoblastoid model for B-cell lymphoma research. Raji cells exhibit rapid proliferation and retain B-cell characteristics, including surface immunoglobulin expression. They are extensively employed to dissect oncogenic signaling, apoptosis, and drug resistance mechanisms. Their genetic tractability allows efficient CRISPR/Cas9-mediated editing, making them an ideal host for generating gene knockouts to explore lymphoma biology.
The CCDC85C gene encodes a protein featuring a coiled-coil domain, a structural motif known to facilitate protein-protein interactions, often serving as a scaffold for multiprotein complex assembly. Beyond this general functional prediction, the molecular role of CCDC85C remains largely uncharacterized. No upstream regulators, downstream effectors, or specific signaling pathways involving CCDC85C have been reported. Current evidence suggests it may interact with other coiled-coil domain-containing proteins, but the physiological partners and consequences are undefined. This knockout model thus provides a crucial tool to dissect CCDC85C’s interactions and its potential integration into cellular networks through biochemical and genetic approaches.
In the Raji Burkitt’s lymphoma context, disruption of CCDC85C can help elucidate its possible contributions to B-cell proliferation, survival, or therapeutic sensitivity. Given the aggressive nature of Burkitt’s lymphoma driven by MYC translocation, unknown modifiers like CCDC85C may play unexpected roles. The polyclonal knockout population reduces clonal bias, enabling more reliable phenotypic screening. It serves as a valuable resource for investigating whether CCDC85C participates in lymphoma maintenance or drug response, potentially uncovering new vulnerabilities or targets for intervention.
This product supports diverse research applications including functional genomics, drug target validation, and investigation of coiled-coil protein networks. Standard assays such as Western blot and RT-qPCR can confirm knockout efficacy; viability assays like MTT and CellTiter-Glo assess proliferation; flow cytometry with Annexin V/PI staining evaluates apoptosis and cell cycle distribution; co-immunoprecipitation identifies interacting proteins; and RNA-seq reveals transcriptome-wide changes. These experimental strategies allow detailed characterization of CCDC85C’s biological role in B-cell lymphoma. For technical assistance or further details, please contact Ascent Research.
